|Day Low/High||67.84 / 68.75|
|52 Wk Low/High||65.06 / 100.23|
They offer impressive free cash flow, great balance sheets, evolving pipelines and nice dividend yields.
The market's major indices are getting worse as the morning progresses. There are deep losses across the board, with the Nasdaq Composite down nearly 3% at last check. Maybe we'll get some relief from the European markets closing. Oil is holding its...
In a year's time, investors may look back and think this was a great entry point.
Celgene, AbbVie and Gilead are set to report earnings. Here's what to look for.
The year has not started the way most pundits and prognosticators had envisioned.
It was all about the FANGs in 2015, but go for value plays this year.
Ireland’s Shire has clinched Baxalta with a stock and cash deal worth $32 billion on Monday.
Look for market leadership to shift as the U.S. economy plods along.
5 biotech stocks that could outperform the overall market in 2016.
United Kingdom-based AstraZeneca agreed to acquire a 55% stake in Dutch Acerta Pharma in a $4 billion deal, the company announced on Thursday.
The merged company can become multiple companies.
History indicates pharmaceutical companies with low multiples offer payoffs down the road.
Look for 2015's record run of mergers and acquisitions to continue.
Here is where to find value next year.
The market has strengthened some since my last update. Apple (AAPL) definitely seems to acting better since its earnings report, and is back above some important moving-day averages. Jim Cramer is right about the stock -- it's one you should hold, n...
AbbVie, Teva and Zimmer Biomet posted solid quarters and are upbeat about the road ahead.
In Monday's analysts' actions, one Wall Street firm is weighing in on the Hewlett Packard split and another firm is giving Abbvie (ABBV) a rating and target price boost.
Stocks ended slightly lower Friday, but enjoyed their best monthly gain in four years in October.
Markets are now up slightly in what is one of most listless trading sessions to end a month that I recall lately. Not much moving. As previously noted, AbbVie (ABBV) might be the standout in the S&P 500 today. It's up more than 10% in trading today...
Futures are up as we get less than an hour from the opening bell for October's last trading day. Earnings reports continued to hit fast and furious this morning, as about one third of S&P 500 companies report quarterly numbers this week. Here are th...